DoD Lung Cancer, Idea Development Award | W81XWH 22 LCRP IDA

Opportunity Information: Apply for W81XWH 22 LCRP IDA

The DoD Lung Cancer Research Program (LCRP) Idea Development Award (FY22) is designed to fund early-stage, conceptually new lung cancer research ideas that are not yet fully developed but could generate compelling initial data and open up entirely new directions for the field. The intent is to back high-risk, high-reward projects that may be too exploratory for other funding mechanisms, but that could realistically lead to critical discoveries or major advances that help reduce deaths and suffering from lung cancer. Projects focused only on mesothelioma are explicitly not allowed under this opportunity. Applications are expected to be grounded in a clear, well-constructed, and testable hypothesis supported by strong scientific rationale.

A central expectation of this award is that applicants do more than propose solid science; they must make a convincing case for both innovation and impact. Innovation, in this context, means the work should introduce a fresh paradigm, challenge existing assumptions, or approach a known problem from an unusually creative angle rather than simply extending incremental prior work. Impact means the project should have a credible pathway to producing results that could meaningfully shift lung cancer research and, ultimately, patient outcomes, even if a direct clinical deliverable is not immediate. Reviewers are looking for applicants to spell out, in plain terms, what is truly new about the approach and why the results could matter in a big way. Proposals that are scientifically strong but read as incremental or lacking clear high-impact potential are considered outside the intent of the mechanism.

Although these are early-stage ideas, the program still requires preliminary data to demonstrate feasibility of the hypothesis and the proposed approach. Importantly, those preliminary data do not have to come from lung cancer specifically; feasibility evidence from related systems, models, technologies, or comparable diseases can be acceptable as long as the applicant clearly explains why those data support the proposed lung cancer work.

The opportunity also places meaningful emphasis on supporting early-career scientists through a dedicated New Investigator category. This category is intended for independent investigators within 10 years of their first faculty appointment (or equivalent), allowing them to compete in a separate pool from established investigators during both peer review and programmatic review. New Investigators are strongly encouraged to collaborate with experienced lung cancer researchers and/or experts who bring needed capabilities (for example, clinical lung cancer insight, advanced computational methods, exposure science, imaging, or specialized model systems). The application must clearly explain how these collaborations fill gaps in the principal investigator's background and strengthen the project’s ability to answer the research question. New Investigator applicants must also meet specific eligibility criteria described in the funding announcement.

Another defining feature is the requirement to demonstrate relevance to military health. The LCRP is part of the Defense Health Program mission space, so projects are expected to connect in a meaningful way to the needs of Service Members, Veterans, and their families (Military Health System beneficiaries). Applicants are encouraged to show this relevance through concrete elements such as using military or Veteran populations, biospecimens, or databases; partnering with Department of Defense or Department of Veterans Affairs investigators; or addressing lung cancer factors particularly pertinent to military communities. The announcement specifically notes that this can include environmental exposures other than tobacco, recognizing that military-related exposures and service-connected contexts may shape lung cancer risk, biology, detection, or care needs.

Administratively, the funding opportunity is offered by the Department of Defense (Department of the Army, USAMRAA) under opportunity number W81XWH-22-LCRP-IDA. It is listed as a discretionary opportunity and may be supported through either grants or cooperative agreements. Eligibility is described as unrestricted (open to any type of entity), subject to any clarifications in the announcement. The posting indicated an anticipated total of about 12 awards. The original application closing date listed for this FY22 cycle was July 27, 2022, and the opportunity is associated with CFDA number 12.420.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Lung Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by Jul 27, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 12 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 LCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: